DMab every 6 months, for 2 years, after having received a placebo during the previous 3 years [19]. In conclusion, we describe for the first time the development of ONJ following tooth extraction, in a male patient, treated for idiopathic osteoporosis with DMab. Due to the constant increase in DMab prescription, for the management of osteoporosis, in both genders, physicians should be made aware of this potential risk. Conflicts of interest J.Y.
Reginster has received consulting fees or paid advisory boards from Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed, NPS, and Theramex; lecture fees when speaking at the Protein Tyrosine Kinase inhibitor invitation of a commercial sponsor from Merck Sharp and Dohme, Lilly, Rottapharm, IBSA, Genevrier, Novartis, Servier, Roche, GlaxoSmithKline, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, Theramex, Nycomed, HM781-36B and Novo-Nordisk; and grant support from Bristol Myers Squibb, Merck Sharp & Dohme, Rottapharm, Teva, Eli Lilly, Novartis, Roche, GlaxoSmithKline, Amgen, and HMPL-504 datasheet Servier. A. Neuprez received travel grant from Amgen and Servier. S. Coste received travel grant from Amgen and Servier. E. Rompen has no conflict of interest. J.M. Crielaard has no conflict of interest. Open Access This article is distributed under the terms of the Creative Commons Attribution
Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. References 1. Kaufman JM,
Reginster JY, Boonen S, Brandi ML, Cooper C, Dere W, Devogelaer JP, Diez-Perez A, Kanis JA, McCloskey E, Mitlak B, Orwoll E, Ringe JD, Weryha G, Rizzoli R (2013) Treatment of osteoporosis in men. Bone 53:134–144PubMedCentralPubMedCrossRef 2. Kaufman JM, Goemaere S (2008) Osteoporosis in men. Best Pract Res Clin Endocrinol Metab 22:787–812PubMedCrossRef 3. Rizzoli R, Boonen S, Brandi ML, Bruyère O, Cooper C, Kanis JA, Kaufman JM, Ringe JD, Weryha G, Reginster JY (2013) Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin 29:305–313PubMedCrossRef 4. Cavalier E, Delanaye P, Moranne O (2013) Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis Ribociclib : implications for clinical decision making. Am J Kindey Dis 61:847–848CrossRef 5. Johansson H, Kanis JA, McCloskey EV, Oden A, Devogelaer JP, Kaufman JM, Neuprez A, Hiligsmann M, Bruyère O, Reginster JY (2011) A FRAX° model for the assessment of fracture probability in Belgium. Osteoporos Int 22:453–461PubMedCrossRef 6. Neuprez A, Johansson H, Kanis JA, McCloskey EV, Oden A, Bruyère O, Hiligsmann M, Devogelaer JP, Kaufman JM, Reginster JY (2009) A FRAX model for the assessment of fracture probability in Belgium. Rev Med Liège 64:612–619PubMed 7.